Network Meta‐Analysis: Efficacy of Biological Therapies and Small Molecules as Maintenance Therapy in Ulcerative Colitis
Alimentary Pharmacology & Therapeutics · 2025-07 · 62 (1) · 4-21
DOI: 10.1111/apt.70209 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 23.05.2025. Verfasst von Brigida Barberio und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Oncology and Gastroenterology (DISCOG), Gastroenterology Unit, University of Padova-Azienda Ospedaliera di Padova, Padova, Ita…. Hauptthemen laut MEDLINE: Biological Products, Biological Therapy, Colitis, Ulcerative. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Numerous biologics and small molecules are licensed as maintenance therapy for ulcerative colitis (UC). Differences in the design of randomised controlled trials (RCTs) have not been considered when comparing efficacy between them.
Aims
To examine the relative efficacy of biologics and small molecules by network meta‐analysis according to trial design.
Methods
We searched the literature to 27 February 2025 for RCTs. We judged efficacy using clinical remission, endoscopic improvement, endoscopic remission, or corticosteroid‐free remission and according to previous exposure or non‐exposure to advanced therapies. Random effects model with data reported as pooled relative risks (RR) with 95% confidence intervals (CI); drugs ranked by p ‐score.
Results
We identified 28 RCTs, 16 re‐randomising 6568 patients and 12 treating through 3771 patients. In re‐randomised studies, upadacitinib 30 mg o.d. ranked first for clinical remission (RR of failure to achieve clinical remission = 0.52; 95% CI 0.44–0.61, p ‐score 0.99) and endoscopic improvement (RR = 0.43; 95% CI 0.35–0.52, p ‐score 0.99). Vedolizumab 300 mg 4‐weekly ranked first for endoscopic remission (RR = 0.73; 95% CI 0.64–0.84, p ‐score 0.92) and guselkumab 200 mg 4‐weekly first for corticosteroid‐free remission (RR = 0.40; 95% CI 0.28–0.55, p ‐score 0.95). In treat‐through studies, etrasimod 2 mg o.d. ranked first for clinical remission (RR = 0.73; 95% CI 0.64–0.83, p ‐score 0.88) and infliximab 10 mg/kg 8‐weekly first for endoscopic improvement (RR = 0.64; 95% CI 0.56–0.74, p ‐score 0.94).
Conclusion
In network meta‐analysis, upadacitinib and etrasimod were consistently efficacious as maintenance therapy in UC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Oncology and Gastroenterology (DISCOG), Gastroenterology Unit, University of Padova-Azienda Ospedaliera di Padova, Padova, Italy.
- Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.
- Leeds Institute of Medical Research, St. James's, University of Leeds, Leeds, UK.
ORCID-Profile: Brigida Barberio, Christopher J Black, Alexander C Ford
Zitieren
APA
Barberio, B., Gracie, D. J., Black, C. J., & Ford, A. C. (2025). Network Meta‐Analysis: Efficacy of Biological Therapies and Small Molecules as Maintenance Therapy in Ulcerative Colitis. Alimentary Pharmacology & Therapeutics, 62(1), 4-21. https://doi.org/10.1111/apt.70209
Vancouver
Barberio B, Gracie DJ, Black CJ, Ford AC. Network Meta‐Analysis: Efficacy of Biological Therapies and Small Molecules as Maintenance Therapy in Ulcerative Colitis. Alimentary Pharmacology & Therapeutics. 2025;62(1):4-21. doi:10.1111/apt.70209
BibTeX
@article{Barberio2025,
author = {Barberio, Brigida and Gracie, David J and Black, Christopher J and Ford, Alexander C},
title = {Network Meta‐Analysis: Efficacy of Biological Therapies and Small Molecules as Maintenance Therapy in Ulcerative Colitis},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
volume = {62},
number = {1},
pages = {4--21},
doi = {10.1111/apt.70209}
}
EUVIMED